Posted on 30/11/2009 in Pharmaceutical Company Product News Boehringer-Ingelheim has revealed that Micardis (telmisartan) - its treatment for the reduction of cardiovascular (CV) morbidity risk - has been approved by the European commission (EC).
It has been indicated for use in patients suffering from manifest atherothrombotic CV disease or type 2 diabetes with documented target organ damage.
The EC's recommendations have been made following the results of clinical trials which showed that Micardis has the potential to prevent one in five serious CV events.
"These approvals clearly demonstrate the unique treatment option that Micardis now provides to both physicians and patients as the only medication in the ARB class to provide proven CV protection," explained professor Giuseppe Mancia, chairman of the department of clinical medicine at the University of Milan.
In other Boehringer-Ingelheim news, the firm announced earlier this month that its drug flibanserin passed the phase III trials stage and was shown to ease the stresses associated with hypoactive sexual desire disorder.Other news stories from 30/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
